ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Lymphopenia,Leukopenias NEC,White blood cell disorders,Blood,N
2,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2,2,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
3,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
3,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3,4,Gene mutation identification test positive,Gene analyses,Cytogenetic investigations and genetic analyses,Inv,N
3,5,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
3,6,Inflammation,Inflammations,General system disorders NEC,Genrl,N
3,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3,9,Tumour flare,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
4,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
4,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
4,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4,5,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
4,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4,7,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4,8,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
4,9,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
5,1,Drug clearance decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
5,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
5,3,Infusion site extravasation,Infusion site reactions,Administration site reactions,Genrl,N
5,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
5,5,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
5,6,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
6,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
6,2,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
7,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
7,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
7,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
7,4,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
7,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
7,6,Pelvic pain,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
7,7,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
7,8,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
8,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
9,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
10,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
11,1,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
12,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
12,2,Prostatic specific antigen abnormal,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
13,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
13,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
13,3,Hormone-refractory prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
13,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
13,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
13,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
13,7,Prostatic mass,"Prostatic signs, symptoms and disorders NEC",Prostatic disorders (excl infections and inflammations),Repro,N
13,8,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
14,1,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
14,2,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
15,1,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
15,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
16,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
17,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
18,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
18,2,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,Y
19,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
19,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
